Relation of NSAIDs, DMARDs, and TNF Inhibitors for Ankylosing Spondylitis and Psoriatic Arthritis to Risk of Total Hip and Knee Arthroplasty
J Rheumatol. 2021 Dec;48(12):1892. doi: 10.3899/jrheum.200453.C1.NO ABSTRACTPMID:34853165 | DOI:10.3899/jrheum.200453.C1
CONCLUSION: While implementation of COVID-19 vaccination programs has differed globally, these Canadian estimates are the first to reassuringly show higher COVID-19 vaccine uptake among individuals with IMIDs.PMID:35034001 | DOI:10.3899/jrheum.211148
ConclusionsGiven new options offered by digital technology, its widespread use in many fields, and the importance of patient safety as a topic, there is an imperative for pharmaceutical companies and regulators to work together to establish a way forward for the use of digital options for aRMMs. This study is limited in its generalizability but offers some ideas for future research directions.
With the advent of classification criteria for psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA), patients with axial manifestations associated with psoriasis, initially described in the l950s as a specific entity termed psoriatic spondylitis (PS), are now categorized within PsA, ankylosing spondylitis (AS), and axSpA. Thus, different terms are used to describe axial disease in patients with PsA including PS, axial psoriatic arthritis (axPsA), and psoriatic spondyloarthritis. Patients with PS may present with inflammatory and/or mechanical back pain, but also may display axial disease on imaging despite not com...
Front Med (Lausanne). 2021 Dec 14;8:792846. doi: 10.3389/fmed.2021.792846. eCollection 2021.ABSTRACTThe principle of ketogenic diet (KD) is restriction of carbohydrates to a maximum of 5-10% of the total daily caloric intake, aiming at shifting body metabolism toward ketone bodies. Different studies suggested promising results of KD to help patients to lose weight, to reduce insulin requirements in diabetes, to supplement cancer protocols, to treat neurological conditions and to optimize control of metabolic and cardiovascular diseases. However, literature about the anti-inflammatory properties of KD in rheumatic diseases ...
Does treatment with secukinumab increase the risk of malignancy in patients being treated for psoriasis, psoriatic arthritis, or ankylosing spondylitis?The British Journal of Dermatology
Conditions: Moderate to Severe Plaque Psoriasis; Psoriatic Arthritis; Ankylosing Spondylitis; Non-radiographic Axial Spondyloarthritis Intervention: Other: secukinumab Sponsor: Novartis Pharmaceuticals Not yet recruiting